Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1261-1280 of 1,743 trials

Dilated Cardiomyopathy: Anakinra Treatment Study

We are investigating whether the medication Anakinra can improve heart function in people with dilated cardiomyopathy. This study compares Anakinra plus standard care to standard care alone.

Inflammatory Dilated Cardiomyopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Glioblastoma: Bevacizumab with Radiochemotherapy

We are studying a new treatment approach for patients with newly diagnosed glioblastoma to see if it improves survival and quality of life. The trial also evaluates safety and cognitive effects.

Glioblastoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Soft-Tissue Sarcomas: Next-Generation Sequencing Study

We are exploring whether high-throughput molecular analysis can help guide treatment for patients with advanced soft-tissue sarcomas. This study will compare treatment outcomes for those receiving NGS-guided therapy versus standard care.

Unresectable Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Head and Neck Cancer: Shortened Chemotherapy with Pembrolizumab

We are studying a shorter chemotherapy treatment combined with Pembrolizumab for patients with PD-L1-positive recurrent or metastatic head and neck cancer. The goal is to see if this approach is effective and safe compared to standard treatments.

Head and Neck Squamous Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

MDS and AML: Venetoclax with Azacitidine

We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.

Acute Myeloid LeukemiaMyelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Pemphigus: Personalized Treatment Strategy vs. Standard Care

We are studying whether a personalized treatment plan based on specific blood markers can reduce relapse rates in pemphigus patients compared to standard treatment with rituximab and corticosteroids.

Pemphigus Diseases>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesDermatologyRheumatology

Acute Hyperkalemia: Comparing Treatments

We are studying whether insulin/dextrose infusion, nebulized salbutamol, or their combination is more effective in lowering high potassium levels in emergency patients. This research aims to find the best first-line treatment for acute hyperkalemia.

High Potassium Levels>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesEndocrinologyInternal Medicine

Sarcomas: New Treatment Approach with DDR-Inhibition

We are exploring a new combined treatment for patients with sarcomas to see if it is safe and effective. This study aims to improve treatment options for those affected by this type of cancer.

Non-Metastatic Soft Tissue Sarcoma>2 yearsSafety phase (I)OncologyOrthopedics and Traumatology

Hepatocellular Carcinoma: Durvalumab and Tremelimumab Study

We are comparing two treatment methods for patients with liver cancer to see if combining immune therapy with chemotherapy improves outcomes. The study will assess effectiveness, safety, and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesHepatologyOncology

Emergency Tracheal Intubation: New Optimization Strategy

We are studying a new method for emergency tracheal intubation to see if it reduces complications in adult patients. This approach combines medication and ventilation techniques to improve patient safety during emergencies.

Respiratory Distress>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard Medicines

Squamous Cell Carcinoma: Cetuximab with or without Paclitaxel

We are studying the effectiveness of cetuximab alone or with paclitaxel for patients with recurrent head and neck cancer after previous treatment. The goal is to see how these options affect survival and quality of life.

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Peripheral T-Cell Lymphoma: New Drug Evaluation

We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.

Relapsed or Refractory Peripheral T-Cell Lymphomas>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Bladder Cancer: Sacituzumab Tirumotecan Study

We are investigating the effects of sacituzumab tirumotecan in individuals with bladder cancer. This study aims to see how well this treatment works compared to standard options.

Intermediate-risk Non-muscle Invasive Bladder Cancer>2 yearsSafety phase (I)Efficacy phase (II)OncologyUrology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Septic Shock: Ivabradine for Heart Rate Control

We are studying whether Ivabradine can help control heart rate and improve survival in patients with septic shock. This trial compares the medication to a placebo to assess its effectiveness.

Septic Shock>2 yearsConfirmation phase (III)Standard MedicinesCardiologyInfectious DiseasesInternal Medicine

Mitapivat for Children with Pyruvate Kinase Deficiency

We are studying whether Mitapivat can help increase hemoglobin levels in children with Pyruvate Kinase Deficiency who do not receive regular blood transfusions. This trial compares the treatment to a placebo to assess its effectiveness.

Pyruvate Kinase Deficiency Anemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteHematologyPediatrics

Accelerator-based BNCT for Head and Neck Cancer

We are exploring a new treatment method for patients with head and neck carcinoma. This study aims to see if it can improve outcomes compared to standard therapies.

Head and Neck Cancer>2 yearsSafety phase (I)OncologyOtolaryngology